Thyroid diseases articles from across Nature Portfolio

In 2022, the activation mechanism of TSH receptor (TSHR) by TSH and autoantibodies was demonstrated, monocarboxylate transporter 8 (MCT8) deficiency was corrected with gene therapy in mice and mutant thyroid hormone receptor α (TRα) was activated with a synthetic ligand. These results offer translational perspectives for patients with common and rare diseases affecting these proteins.

Immune checkpoint inhibitor therapies induce potent anti-tumour immunity as well as immune-related adverse events that manifest as autoimmune disease — particularly thyroiditis. Translational studies and preclinical models are beginning to unravel the molecular processes that mediate these adverse events; this knowledge might enable the development of ICIs with anti-tumour efficacy and improved safety margins.